Serum CA125 and HE4 levels as predictors for optimal interval surgery and platinum sensitivity after neoadjuvant platinum-based chemotherapy in patients with advanced epithelial ovarian cancer

Pélissier, A.; Roulot, Aurélie; Guery, B; Bonneau, Claire; Bellet, Dominique; Rouzier, Roman

doi:10.1186/s13048-016-0270-7

Cited by 29 publications

(24 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the neoadjuvant setting, CA125 can be utilized as a marker to assess the response to chemotherapy. The post-NACT CA125 level can predict the possibility of achieving optimal cytoreduction in IDS [36][37][38].…”

Section: Discussionmentioning

confidence: 99%

The Added Value of CA125 Normalization Before Interval Debulking Surgery to the Chemotherapy Response Score for the Prognostication of Ovarian Cancer Patients Receiving Neoadjuvant Chemotherapy for Advanced Disease

Liang

Lijuan

et al. 2020

Preprint

View full text Add to dashboard Cite

Objective: To investigate whether CA125 normalization following neoadjuvant chemotherapy (NACT) can complement the chemotherapy response system (CRS) in the prognostication of patients with tubo-ovarian high-grade serous carcinoma (HGSC).Methods: In total, 106 HGSC patients who received NACT followed by interval debulking surgery (IDS) for FIGO stage IIIC-IV disease were included, and their clinical data were retrospectively reviewed. The primary endpoint was progression-free survival (PFS). Cox regression analysis was performed to identify predictors of PFS.Results: Following NACT, CRS3 was noted in 24 patients (22.6%), and CA125 normalization (≤ 35 U/ml) was noted in 54 patients (50.9%). Both CRS3 and CA125 normalization were identified as independent prognosticators of PFS. Combining these two factors, we stratified the 106 patients into three groups with different risks of recurrence: low-risk group (CRS3 + post-NACT CA125≤ 35 U/ml; n = 17, 16.0%), intermediate-risk group (CRS3 + post-NACT CA125 > 35 U/ml; n = 7, 6.6%) and high-risk group (CRS1-2; n= 82, 77.4%). The differences in PFS between the three groups were significant (log-rank test, P < 0.0001). In Cox regression analyses, the new stratification method was found to have an independent prognostic effect.Conclusion: Both the CRS system and the normalization of CA125 following NACT could reliably predict the risk of recurrence following primary treatment. The combination of the two factors refined the prognostic stratification of HGSC patients who were treated with NACT and IDS.

show abstract

Section: Discussionmentioning

confidence: 99%

The Added Value of CA125 Normalization Before Interval Debulking Surgery to the Chemotherapy Response Score for the Prognostication of Ovarian Cancer Patients Receiving Neoadjuvant Chemotherapy for Advanced Disease

Liang

Lijuan

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Emerging studies suggest that HE4 over-expression promotes ovarian tumour growth and imparts strong resistance against the most commonly used therapeutics [20][21][22][23][24]. Emerging studies suggest that HE4 over-expression promotes ovarian tumour growth and imparts strong resistance against the most commonly used therapeutics [20][21][22][23][24].…”

Section: Discussionmentioning

confidence: 99%

“…HE4 is known to be over-expressed highly in ovarian cancer, but its causal relationship to ovarian cancer pathogenesis has not been established firmly. Emerging studies suggest that HE4 over-expression promotes ovarian tumour growth and imparts strong resistance against the most commonly used therapeutics [20][21][22][23][24]. Interestingly, ovarian cancer patients who experienced greater HE4 reduction during neoadjuvant chemotherapy exhibit improved overall survival [24].…”

Section: Discussionmentioning

confidence: 99%

HE4 suppresses the expression of osteopontin in mononuclear cells and compromises their cytotoxicity against ovarian cancer cells

James

Cantillo

Oliver

et al. 2018

Clinical and Experimental Immunology

View full text Add to dashboard Cite

Ovarian cancers are known to evade immunosurveillance and to orchestrate a suppressive immune microenvironment. Here we examine the role of human epididymis protein 4 (HE4), an ovarian cancer biomarker, in immune evasion. Through modified subtractive hybridization analyses we have characterized the gene targets of HE4 in human peripheral blood mononuclear cells (PBMCs), and established a preliminary mechanism for HE4-mediated immune failure in ovarian tumours. Upon exposure of purified PMBCs to HE4, osteopontin (OPN) and dual-specificity phosphatase 6 (DUSP6) emerged as the most suppressed and up-regulated genes, respectively. SKOV3 and OVCAR8, human ovarian carcinoma cell lines, exhibited enhanced proliferation in conditioned media from HE4-exposed PBMCs, an effect that was attenuated by the addition of recombinant OPN or OPN-inducible cytokines [interleukin (IL)-12 and interferon (IFN)-Ɣ]. Additionally, upon co-culture with PBMCs, HE4-silenced SKOV3 cells were found to be more susceptible to cytotoxic cell death. The relationship between HE4 and OPN was reinforced further through the analysis of serous ovarian cancer patient samples. In these biopsy specimens, the number of OPN T cells correlated positively with progression free survival (PFS) and inversely with serum HE4 level. Taken together, these findings show that HE4 enhances ovarian cancer tumorigenesis by compromising OPN-mediated T cell activation.

show abstract

“…Through the previous cytotoxicity assay 41 , we found that the IC50 of A2780 and OVCAR3 respectively was 30 μM and 45 μM to cispaltin. A2780 as relative sensitivity, and OVCAR3 as relative resistance.…”

Section: Ovarian Carcinoma Cell Lines and Culturementioning

confidence: 91%

The Detection of sAMY1α in Ovarian Cancer Ascites During First-Line Chemotherapy Predict the Response of Patients to Treatment

Kong

Liu

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Ovarian cancer ascites are a clinical conundrum in the process of diagnosis and treatment, and chemotherapy is the main treatment. The efficacy and prognostic assessment of chemotherapy has been the subject of continuous exploration. Methods: Affymetrix HTA2.0 microarray analysis of ovarian cancer ascites without and with chemotherapy, as well as metabolomics techniques, showed that AMY1A gene expression in the chemotherapy was significantly higher than that without chemotherapy.Results: The analysis of ovarian cancer tissues, ascitic precipitated cells and supernatants, showed that the high expression of sAMY-1α was negatively correlated with HE4 (p<0.01), and was also negatively correlated with the expression of the Beclin1 and LC3 (p<0.05, p<0.001) in group with chemotherapy. The results of ovarian cancer cell lines OVCAR3 and A2780, which were treated with autophagic inhibitor (3MA), inducer (rapamycin) or cisplatin (CDDP), were consistent with it. The results of 3MA group showed that as the drug concentration increased, there were decreased in the levels of Beclin1 and LC3II, and sAMY1α levels increased. There was opposite result in rapamycin group. CDDP group revealed significantly decreased levels of LC3II, Beclin1, and increased levels of sAMY1α; when rapamycin was added, autophagy inhibition was alleviated, and slightly reduced levels of sAMY1α. The results indicated that chemotherapy induced autophagic death of tumor cells, and the expression of sAMY1α in ascites of chemotherapy reflected the degree of autophagic death of tumor cells. Conclusions: During the diagnosis and treatment of ovarian cancer ascites, the expression level of sAMY1α was detected at any time, compared with the levels of HE4, Beclin1 and LC3 in the ascites with chemotherapy, and compared with the serum level of CA125 in the patients, so that the recurrence of ascites could be predicted. Therefore, the adjustment of treatment regimen has important guiding significance.

show abstract

Serum CA125 and HE4 levels as predictors for optimal interval surgery and platinum sensitivity after neoadjuvant platinum-based chemotherapy in patients with advanced epithelial ovarian cancer

Cited by 29 publications

References 29 publications

The Added Value of CA125 Normalization Before Interval Debulking Surgery to the Chemotherapy Response Score for the Prognostication of Ovarian Cancer Patients Receiving Neoadjuvant Chemotherapy for Advanced Disease

The Added Value of CA125 Normalization Before Interval Debulking Surgery to the Chemotherapy Response Score for the Prognostication of Ovarian Cancer Patients Receiving Neoadjuvant Chemotherapy for Advanced Disease

HE4 suppresses the expression of osteopontin in mononuclear cells and compromises their cytotoxicity against ovarian cancer cells

The Detection of sAMY1α in Ovarian Cancer Ascites During First-Line Chemotherapy Predict the Response of Patients to Treatment

Contact Info

Product

Resources

About